Clinical Medicine Insights: Oncology

Study Shows Artificial Intelligence Successfully Detects Eye Disease in Children with Diabetes

Retrieved on: 
Thursday, November 16, 2023
Eye, Ophthalmology, Type, Telehealth, Prevalence, Orbis International, Endocrinology, Risk, Disease, Clinical Medicine Insights: Oncology, Patient, Visual impairment, Algorithm, Artificial intelligence, Intelligence, Diabetes, AI, Medicine, Diabetic retinopathy, Paratriathlon, Medical device, Dietary supplement, Orbis

NEW YORK, Nov. 16, 2023 /PRNewswire/ -- A new study by eye care nonprofit Orbis International finds that artificial intelligence (AI) accurately detects diabetic retinopathy, a common complication of diabetes that can lead to blindness, in children and young adults. The peer-reviewed study, published in Clinical Medicine Insights: Endocrinology and Diabetes, shows that Cybersight AI, a component of Orbis's telemedicine and e-learning platform, can be an effective tool to support medical staff, who are often overburdened with patient caseloads, to care for children with diabetes, especially in low-resource settings with limited numbers of trained health care professionals.

Key Points: 
  • New research from eye care nonprofit Orbis International is the first ever to use artificial intelligence to detect diabetic retinopathy in children in a low- or middle-income country.
  • NEW YORK, Nov. 16, 2023 /PRNewswire/ -- A new study by eye care nonprofit Orbis International finds that artificial intelligence (AI) accurately detects diabetic retinopathy, a common complication of diabetes that can lead to blindness, in children and young adults.
  • Adults and children with diabetes both require regular eye screenings to detect diabetic retinopathy and keep the condition from progressing, which can lead to irreversible vision loss or blindness.
  • However, trained eye care professionals cannot meet the growing demand for diabetic retinopathy screening as the prevalence of diabetes continues to rise.

Montreal Oncology Medical Team Receives Award for Use of the Belong Beating Cancer Together App

Retrieved on: 
Monday, July 10, 2023
Oncology, English, Jewish General Hospital, Current Oncology, Riau rupiah, Patient, Prix, Clinical Medicine Insights: Oncology, Hope, General Hospital, Health, Nursing, Belong, Medicine

Belong provides Patient Support Programs (PSPs) for a wide variety of healthcare providers and systems globally.

Key Points: 
  • Belong provides Patient Support Programs (PSPs) for a wide variety of healthcare providers and systems globally.
  • The multidisciplinary oncology team guided hundreds of patients with the help of Belong's Beating Cancer Together app.
  • A recent study published by the CIUSSS West-Central Montreal's team in Current Oncology highlights the impact of Belong's app on patient care in their network.
  • "This award confirms our commitment and the excellence of our multidisciplinary oncology team toward patients and their families, which we were able to achieve using Belong's high-engagement platform."

LumaBridge Welcomes Dr. Alexander Stojadinovic as Chief Medical Officer

Retrieved on: 
Tuesday, November 8, 2022
Surgical oncology, MBA, Memorial Sloan Kettering Cancer Center, Hospital, United States service academies, University, Institute, Uniformed Services University of the Health Sciences, Patient, SAN, Bon, Journal of Surgical Oncology, Journal, Program, FACS, Triple accreditation, Drug development, GlaxoSmithKline, MSKCC, Saint Mary's Hospital, Medicine, Maryland School, Walter Reed Army Medical Center, Clinical Medicine Insights: Oncology, Harvard Business School, Partnership, Master of Science, Science, Memorial, European Journal of Cancer, Research, CRO, Outline of health sciences, Health, Strategic planning, Pharmaceutical industry, Management, MD, Cancer, Pharmacy

SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.

Key Points: 
  • SAN ANTONIO, Nov. 8, 2022 /PRNewswire/ -- LumaBridge (formerly known as Cancer Insight), a clinical research organization (CRO) dedicated to discovering, developing, and testing emerging biotechnologies related to cancer therapies, welcomes a new chief medical officer, Alexander Stojadinovic, MD, MBA, MSc, FACS.
  • He brings to LumaBridge his extensive experience in strategic planning, program development, team building, operations, and research and development.
  • Dr. Stojadinovic has served as senior medical director in oncology clinical development at GlaxoSmithKline, as medical director of healthcare management services for Amerigroup Texas, and as a consulting surgical oncologist and healthcare executive.
  • "We are thrilled to welcome Alex to the team," said George E. Peoples, MD, FACS, founder, chief scientific officer, and executive chairman of LumaBridge.

Gradalis Announces Publication of Two Studies Demonstrating the Positive Results of Vigil® in Combination with Checkpoint Inhibitors

Retrieved on: 
Monday, October 3, 2022
Clinical Medicine Insights: Oncology, Phase 1, Cancer, GLOBE, Toxicity, RFS, Trifecta, Neoplasm, PFS, VITAL, Combination, Immunotherapy, Randomized controlled trial, Research, Clinical trial, Relapse, HRP, Population, OS, AstraZeneca, TNBC, List of Nature Research journals, Immune system, Safety, GameChanger, Breast cancer, Large-cell lung carcinoma, Epitope, Patient, PD-L1, The Lancet, American Society of Clinical Oncology, Ovary, Medicine, DNA, Society, GM, Ovarian cancer, BRCA, Pharmaceutical industry, Medical imaging, Vaccine, DALLAS, Woman, Durvalumab

DALLAS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Gradalis, Inc., a privately held, late-stage clinical biotechnology company, today announced a peer-reviewed publication in Clinical Medicine Insights: Oncology demonstrating positive results from a pilot study investigating Vigil® in combination with a PD-L1 checkpoint inhibitor, durvalumab (Imfinzi® - AstraZeneca), in patients with advanced triple negative breast cancer (TNBC) or recurrent/refractory ovarian cancer (OC). This study also suggests that administration of Vigil with durvalumab improved progression free survival (PFS) in patients with PD-L1 positive tumors compared to those with PD-L1 negative tumors.

Key Points: 
  • Vigil is the first cellular immunotherapy to demonstrate survival benefits in a randomized controlled trial of patients with solid tumors.
  • John Nemunaitis, M.D., Chief Scientific Officer of Gradalis commented, These two clinical trials underscore the therapeutic utility of combining Vigil and checkpoint inhibitors without generating incremental toxicity relative to that shown with single agent checkpoint inhibitor therapy.
  • Vigil in combination with durvalumab demonstrated no grade 3 or greater adverse events that were attributed to Vigil by the investigators.
  • Vigil is being studied in other cancer types and has shown positive results in combination with checkpoint inhibitors.